Latest Stock Buy or Sell? Make More Informed Decisions!

This equipment producer is active in Europe and Italy creating renewable natural gas from composting as well as methane collection in garbage dumps in North America. He likes their long term prospects.

It's been painful to own. Their primary drug cured hepatitis C, the holy grail. But there's little recurring revenue here, and it disappointed investors by not reinvesting their cash. However, their new HIV franchise could take market share. A hated stock for a long time, but that sentiment is now changing. Your patience is now being rewarded.

A recent article by a market analyst suggested Canopy (WEED-T) has an advantage with multiple provincial locations and about 5.6 million square feet of space including a 700,000 square foot facility in Quebec expected to be in operation by May this year. He guesses their capacity will be 270 million grams per year, which should project $1.1 billion in annual sales beginning in September most likely. They are a monster in this space.

Likes this. One of the most dominant medtech companies, diversified from hips and knees to cardio. Good 15x forward earnings and a stable dividend yield. It's an economy of scale game in medtech, and MDT is well-positioned. Great
balance sheet and growth profile.

He spoke of a market analyst comment that says this company trades about half the cost on a EBITDA basis compared to Canopy (WEED-T) and other big players. They recently received approval in Quebec.

This company ranks 286 in their database and they do not hold it. There is some concern on future earnings. It is a high-yield company with only a 55% payout ratio, so he feels the dividend is safe. Overall, the debt-to-equity ratio looks reasonable and it is a good hold. If oil prices rise, it will appreciate. He thinks there are better opportunities. Yield 5.2%. (Analysts’ price target is $41)

He says the earnings expectations have been revised downwards my several analysts recently. Their last earnings report had a negative 14% surprise. Although the current P/E is reasonable the free cash flow rate is negative. The dividend looks defendable with a 51% payout ratio. Overall, it is the lack of growth hurting this one and he sees better opportunity elsewhere. Yield 5.4%.

The biggest partnership opportunity for this company in blockchain is with an Italian bank, whose size is similar to BMO. They are profitable and he expects that to accelerate. They are developing new technology that will allow small companies to post a one-page analytical summary of their company for the market. He expects this to add significantly to earnings.

He does not own this company presently, but it ranks highly in their database. They do not pay a dividend despite an 18% ROE and earnings are expected to grow. They are a highly disciplined company that has been successful at growing by acquisition. Overall, they are waiting for another large acquisition. Yield 0%.

The high yield suggests the dividend might be at risk, however, it has a modest 15% payout ratio. The biggest challenge is that earnings were down 21% and now analysts are revising their earnings down 18%. The stock appears cheap at a 6 times earnings price. At the moment, because of the high-yield he thinks there is more risk than he is comfortable with. Yield 7.4%.

This company takes hydrogen and injects it into diesel engines to reduce emissions and fuel consumption. They have had success selling into Europe and Germany. At the moment they are waiting to see how the rollout goes.

This stock is perpetually in the $16-$18 range, because the owners generally pay out earnings in the form of dividends. The yield is backed by a 76% payout ratio – a little high, but sustainable. Overall, a decent ROE and good cash flow, but he believes there are better opportunities in this dividend space. Yield 4.3%.

This is part of strategy of trades in the particle board space. It has a 19% pay-out ratio and a 17% sales growth. They have reduced debt by 32% and the ROE has improved to 39%. Yield 4.9%. (Analysts’ price target is $49.71 )

This company grows by acquisition with an aviation business in Northern Canada and in the manufacturing sector. A high yield with only a 34% payout ratio and an ROE of 14.9%. Yield 6.6%. (Analysts’ price target is $45.20 )

This company has had a dramatic turnaround in their business, he says, and they do not own it yet. The payout ratio is only 12% and sales are up 45% on the year. ROE is now 27% from negative a year ago. Earnings are expected to be up 35%. Technical analysts suggest if it can break above $81 it can challenge $100 per share. Yield 2.2%. (Analysts’ price target is $81.51 )